Drug Trial Radar · NCT00455507
A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Last checked: Nov 20, 2026Latest source record: Aug 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
363
Actual
Start
Mar 2007
Primary completion
Aug 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's disease (PD) treated with levodopa.
Conditions
- Parkinson's Disease
Interventions
IstradefyllineDrug
Two 10 mg KW-6002 tablets orally once daily for 12 weeks
IstradefyllineDrug
Two 20 mg tablets orally once a day for 12 weeks
PlaceboDrug
Two placebo tablets orally once daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with Parkinson's disease (PD) treated with levodopa/dopa-decarboxylase inhibitor.Time frame: Last Visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.